The European Life Science Strategy along with the Strategy on Research and Technology infrastructures with focus on the treatment of rare diseases

Practical information

• Composition of the study group
• Administrator: Maja RADMAN, Assistant: Sandra ROURA CANO
• TEN section meeting: 3 February 2026
• EESC plenary session:  18-19 February 2026
• Contact: E-mail

Background

At the request of the Cypriot Presidency, the EESC will draft an exploratory opinion on implementing the EU Life Science Strategy and the Strategy on Technology Infrastructures, with a particular focus on improving rare disease treatment.

The Life Science Strategy seeks to establish the EU as a global leader in this field by 2030, transforming research into tangible benefits for health and sustainability. The key element of the strategy is the development of robust R&I ecosystems building on initiatives such as the European Rare Diseases Research Alliance (ERDERA), investments in Advanced Therapy Medicinal Products (ATMPs), the Strategy on Research and Technology Infrastructures or BBMRI-ERIC, the world’s largest human biobank.

The forthcoming EESC opinion will explore how European Partnerships can promote inclusive participation, enhance cross-border cooperation, and strengthen research capacity, while ensuring innovation contributes to quality employment, fair working conditions, and robust social dialogue across the EU.